Prognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs.

IF 0.7 4区医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Journal of Africa Pub Date : 2026-02-20 DOI:10.5830/CVJA-2025-107

Kahraman Cosansu, Sabiye Yilmaz, Cagin Mustafa Ureyen, Mustafa Gokhan Vural

{"title":"Prognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs.","authors":"Kahraman Cosansu, Sabiye Yilmaz, Cagin Mustafa Ureyen, Mustafa Gokhan Vural","doi":"10.5830/CVJA-2025-107","DOIUrl":null,"url":null,"abstract":"Background: The systemic immune-inflammation index (SII) is a simple parameter that has been used to predict adverse outcomes in different clinical settings. The prognostic value of SII, an innovative biomarker of inflammation, in non-valvular atrial fibrillation (NVAF) patients has not been assessed. The aim of this study was to evaluate the prognostic value of SII in NVAF patients who were under direct oral anticoagulant (DOAC) medication.Methods: A total of 467 patients with NVAF treated with DOACs from 2018 to 2021 were retrospectively enrolled in this cohort study. Demographics, medication, and outcome data were collected for each patient. SII was calculated from complete blood counts as the ratio of neutrophil-to-lymphocyte count multiplied by the platelet count. The primary outcome was major adverse events (MAEs), which include major bleeding, stroke, and death.Results: Logistic regression analyses showed that the SII score was an important predictor of outcomes in NVAF patients.Conclusion: The SII may be a successful, non-invasive, and cost-effective parameter for predicting bleeding and stroke in patients with NVAF. It may be used as a useful risk stratification tool for these patients.","PeriodicalId":9434,"journal":{"name":"Cardiovascular Journal of Africa","volume":"37 1","pages":"20-26"},"PeriodicalIF":0.7000,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Journal of Africa","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5830/CVJA-2025-107","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The systemic immune-inflammation index (SII) is a simple parameter that has been used to predict adverse outcomes in different clinical settings. The prognostic value of SII, an innovative biomarker of inflammation, in non-valvular atrial fibrillation (NVAF) patients has not been assessed. The aim of this study was to evaluate the prognostic value of SII in NVAF patients who were under direct oral anticoagulant (DOAC) medication.

Methods: A total of 467 patients with NVAF treated with DOACs from 2018 to 2021 were retrospectively enrolled in this cohort study. Demographics, medication, and outcome data were collected for each patient. SII was calculated from complete blood counts as the ratio of neutrophil-to-lymphocyte count multiplied by the platelet count. The primary outcome was major adverse events (MAEs), which include major bleeding, stroke, and death.

Results: Logistic regression analyses showed that the SII score was an important predictor of outcomes in NVAF patients.

Conclusion: The SII may be a successful, non-invasive, and cost-effective parameter for predicting bleeding and stroke in patients with NVAF. It may be used as a useful risk stratification tool for these patients.

查看原文本刊更多论文

非瓣膜性房颤患者全身免疫炎症指数的预后价值：使用DOACs患者的SII评分。

背景：全身免疫炎症指数（SII）是一个简单的参数，用于预测不同临床环境下的不良后果。SII（一种创新的炎症生物标志物）在非瓣膜性心房颤动（NVAF）患者中的预后价值尚未得到评估。本研究的目的是评估SII在直接口服抗凝药物（DOAC）治疗的非瓣膜性房颤患者中的预后价值。方法：回顾性纳入2018年至2021年接受DOACs治疗的467例非瓣膜性房颤患者。收集每位患者的人口统计、用药和结局数据。SII由全血细胞计数计算，即中性粒细胞与淋巴细胞计数的比值乘以血小板计数。主要结局是主要不良事件（MAEs），包括大出血、中风和死亡。结果：Logistic回归分析显示，SII评分是NVAF患者预后的重要预测指标。结论：SII可能是预测非瓣瓣性房颤患者出血和卒中的一种成功的、无创的、具有成本效益的参数。它可以作为这些患者的一种有用的风险分层工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Journal of Africa CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

1.30

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Cardiovascular Journal of Africa (CVJA) is an international peer-reviewed journal that keeps cardiologists up to date with advances in the diagnosis and treatment of cardiovascular disease. Topics covered include coronary disease, electrophysiology, valve disease, imaging techniques, congenital heart disease (fetal, paediatric and adult), heart failure, surgery, and basic science.